Published: 26 October 2021
Author(s): C. Mettler, CA. Durel, P. Guilpain, B. Bonnotte, F. Cohen-Aubart, M. Hamidou, JC. Lega, V. Le Guern, F. Lifermann, V. Poindron, G. Pugnet, A. Servettaz, X. Puéchal, L. Guillevin, B. Terrier, French Vasculitis Study Group
Issue: March 2022
Section: Concise report

Granulomatosis with polyangiitis (GPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAVs), characterized by granulomatous necrotizing vasculitis of small vessels [1]. Standard of care is based on a combination of glucocorticoids (GCs) and immunosuppressive agents [2]. For remission-induction of organ-threatening or life-threatening GPA, European League Against Rheumatism (EULAR) and French guidelines recommend the use of GCs in combination with either cyclophosphamide (CYC) or rituximab (RTX) [2,3].


Stay informed on our latest news!